Functional mushroom supplements

Functional mushroom supplements — lion’s mane, reishi, cordyceps, turkey tail, chaga — are sold for immune, cognitive and energy effects. The science here is unusually mixed: one mechanism is well characterised at the receptor level, others are supported mainly by in-vitro work, and a large part of the practical question is not pharmacology at all but what is actually in the container.

β-glucans and a real receptor

Fungal cell walls contain β-glucans, glucose polymers with β-1,3 backbones and β-1,6 branches. Mammals have a dedicated receptor for these: dectin-1, a pattern-recognition receptor on macrophages, dendritic cells and neutrophils, which binds β-1,3-glucan and triggers signalling through Syk kinase to activate phagocytosis and cytokine production.

This is genuinely solid ground. Dectin-1 exists because fungal β-glucan is a signature of fungal infection, and its recognition is part of innate immunity. Fungal β-glucans are therefore immunologically active by a defined, structurally specific route — not by a vague “boosting” effect.

Two qualifications matter. Activity depends on structure: degree of branching, molecular weight and solubility all change receptor engagement, so β-glucans from different fungi — and from oats and barley, which are β-1,3/1,4 and do not bind dectin-1 the same way — are not interchangeable. And immune activation is not automatically beneficial; it is a modulation whose clinical consequence has to be demonstrated rather than assumed.

Lion’s mane: two compound families, two tissues

Hericium erinaceus is the cognitive claim, and its chemistry is specific enough to be checkable. Two families of compounds stimulate nerve growth factor synthesis in cell culture: hericenones, found in the fruiting body, and erinacines, found in the mycelium. They are different molecules from different tissues, which means fruiting-body and mycelial products are not equivalent preparations even in principle.

Erinacine A is the more interesting of the two, having been shown to cross the blood–brain barrier in rodents — a property most NGF-related candidates lack. The evidence chain, stated honestly, runs: strong in-vitro NGF induction, supportive rodent work, and a small number of human trials that are short, small and mixed in outcome. The mechanism is real and the human effect is not established.

The test that settles the practical question

Much of the mycelial supplement market is produced by growing fungal mycelium on sterilised grain and harvesting the whole mass, grain included, because separating mycelium from substrate is impractical. The resulting powder can be predominantly grain.

This is measurable rather than a matter of opinion. Grain starch is α-glucan; fungal cell wall is β-glucan. An analysis reporting β-glucan and α-glucan separately shows directly how much of the product is fungal material and how much is starch — and products declaring only “polysaccharides” are reporting a figure that includes the starch. Fruiting bodies typically test at substantially higher β-glucan than mycelium-on-grain.

Extraction method matters for the same reason: β-glucans are extracted with hot water, while triterpenes such as reishi’s ganoderic acids need alcohol, so a single extraction method does not deliver both.

What is weaker

Cordycepin from Cordyceps has demonstrated activity in vitro but is rapidly deaminated in the body by adenosine deaminase, which limits exposure. Most cultivated “cordyceps” supplements are Cordyceps militaris or a related fermented strain, not the wild caterpillar fungus of the traditional literature. Chaga is high in oxalate, which is a genuine consideration for kidney stone risk at sustained high intake.